L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza’s syndrome

This is a preview of subscription content, access via your institution.


  1. 1.

    Zádori D, Veres G, Szalárdy L, Klivényi P, Vécsei L (2015) Drug-induced movement disorders. Expert Opin Drug Saf 14(6):877–890

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Chen JJ (2012) Drug-induced movement disorders. Mental Health Clin 1(7):167–173

    Article  Google Scholar 

  3. 3.

    Teive HA, Munhoz RP, Ferraz HB (2009) Flunarizine and cinnarizine-induced Parkinsonism: 25 years of de Melo-Souza’s syndrome. Arq Neuropsiquiatr 67(3B):957

    PubMed  Google Scholar 

  4. 4.

    Teive HAG, Troiano AR, Germiniani FMB, Werneck LC (2004) Flunarizine and cinnarizine-induced Parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord 10:243–245

    Article  PubMed  Google Scholar 

  5. 5.

    Martin RJ (2004) Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry 75:iii22–iii28

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Pedro-Botet ML, Bonal J, Caralps A (1989) Nifedipine and myoclonic disorders. Nephron 51:281

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Dressler D (2014) Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. J Neural Transm 121:367–369

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Wallace EL, Lingle K, Pierce D, Satko S (2009) Amlodipine-induced myoclonus. Am J Med 122:e7

    Article  PubMed  Google Scholar 

  9. 9.

    Munhoz RP, Bertucci FD, Teive HAG (2017) Not all drug-induced Parkinsonism are the same: the effect of drug class on motor phenotype. Neurol Sci 38:319–324

    Article  PubMed  Google Scholar 

  10. 10.

    Abdo WF, Van De Warrenburg BP, Burn DJ, Quinn NP, Bloem BR (2010) The clinical approach to movement disorders. Nat Rev Neurol 6:29–37

    Article  PubMed  Google Scholar 

  11. 11.

    Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R (1997) Brain pharmacokinetics and in vivo receptor binding of 1, 4-dihydropyridine calcium channel antagonists. Life Sci 61:2083–2090

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Surmeier DJ (2009) A lethal convergence of dopamine and calcium. Neuron 62:163–164

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Swart T, Hurley MJ (2016) Calcium channel antagonists as disease-modifying therapy for Parkinson’s disease: therapeutic rationale and current status. CNS Drugs 30:1127–1135

    Article  CAS  Google Scholar 

Download references


Elderly Pharmacovigilance Programme has funding support from the National Programme for Healthcare of the Elderly, Ministry of Health and Family Welfare, Government of India.

Author information



Corresponding author

Correspondence to Sankha Shubhra Chakrabarti.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Elderly Pharmacovigilance Programme has the institutional ethics committee approval no. Dean/2015-16/IEC/411.

Informed consent

Written informed consent was taken from patient’s legal guardian (son) for publication of case and videos.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kaur, U., Das, P., Gambhir, I.S. et al. L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza’s syndrome. Neurol Sci 40, 1077–1080 (2019). https://doi.org/10.1007/s10072-018-3662-1

Download citation